14 RESULTS
COMMENT Early termination of studies 301 and 302 and a dose increase midway through the trial led to an incomplete dataset and clearly complicate the interpretation of the results. However, the totality of the data provides evidence of dose-related lowering of ...
COMMENT We were disappointed that the DIAN-TU trial did not meet its primary cognitive endpoint. The small sample that combined preclinical and symptomatic patients, variable range in expected time to disease onset, and late escalation to the high dose may have ...
COMMENT We have postponed observational study visits but are continuing study infusions for now. Participant attendance is good, but we have seen a mild increase in cancellations because some retirement communities are encouraging residents to stay home, plus ...
COMMENT DIAN-TU is a visionary study comprising valiant volunteers. The negative primary outcome is disappointing. Additional analyses are underway to learn as much as we can about Alzheimer’s disease from this trial. A platform has been created and is moving ...
COMMENT Approval in China for a new treatment for Alzheimer’s disease is encouraging. We await publication of the study that led to approval. From the data presented at CTAD, cholinesterase inhibitors were not allowed and the drug worked best for those with a ...
COMMENT It was very disappointing to learn that Biogen plans to close the ENGAGE trial because of lack of efficacy on the interim analysis. We had been eagerly looking forward to the results next year and this came out of the blue. This antibody did not work for ...
COMMENT I am cautiously optimistic. The reported level of amyloid lowering was surprisingly high, more than 80 percent amyloid negative by visual read. This is interesting in that the antibody has higher affinity for protofibrils than plaques. The cognitive ...
COMMENT This new framework is the natural evolution of the 2011 NIA-AA and earlier IWG guidelines. The authors are thoughtful and innovative in their attempt to unify the Alzheimer’s biomarker and clinical continuum. They acknowledge that a number of important ...
COMMENT These are very encouraging preliminary results from the IDEAS trial showing that amyloid imaging has a major impact on clinical diagnosis and treatment. These data provide further evidence that many patients with memory loss probably do not have Alzheimer ...
COMMENT The potential to obtain a reliable quantitative imaging measure of synaptic density would be a great advance in AD biomarker research. This report of 11C UCB-J, which binds to protein SV2A, may be a good first step toward this goal. Though the ...
COMMENT This is an interesting manuscript. The data fits with the diagnostic staging of preclinical AD proposed by the NIA-AA work group in 2011. This extends earlier findings that low CSF Aβ associates with eventual decline in amnestic MCI but that decline ...
COMMENT These findings by Mattsson and colleagues are consistent with recent reports that cognitively normal elderly with PIB retention close to the cutoff at baseline were more likely to show higher rates of retention on follow-up scans than those with low ...
COMMENT The FDA draft guidance represents a positive step forward in the development of new treatments for early stages of Alzheimer’s disease (AD). The FDA guidance and editorial recognize that older individuals with evidence of amyloid pathology are at high ...
COMMENT Neuroimaging in Dementia is a gem of a book, highly recommended for current and future clinicians and clinical researchers interested in the care of patients with cognitive decline. Beautifully illustrated and well-balanced, its intelligent design ...
